MorphoSys and Heptares Therapeutics signed an agreement to discover novel antibody therapeutics targeting GPCRs. Heptares will generate stabilized receptors (StaRs®) for a set of GPCR disease targets ...
Structure Therapeutics IncGPCR shares are up on Wednesday, probably in reaction to the U.S. Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results